Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Can-Fite BioPharma Ltd.

< Previous 1 2 3 4 Next >
Can-Fite to Present at Dermatology Drug Development Summit Europe on April 6, 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite: Namodenoson’s Treatment of Liver Fibrosis Receives Notice of Allowance from U.S. Patent Office
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can Fite Announces First Patient Enrolled in Phase IIb NASH Clinical Trial with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Issues Letter to Shareholders
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Following Complete Clearance of Cancer Lesions in Advanced Liver Cancer Patient, Can-Fite is Filing Patent Applications for the Treatment of Various Advanced Solid Tumors
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Liver Cancer Patient Treated with Can-Fite’s Namodenoson Clears All Cancer Lesions Under Open Label Extension of Phase II Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Phase III Psoriasis Study to Complete 16-Week Treatment of Last Patient in January; Topline Data Expected Q1 2022
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite CEO Dr. Pnina Fishman to be Guest Speaker at 5th Annual NASH Summit 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Piclidenoson Commences Clinical Study for the Treatment of Canine Osteoarthritis
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at H.C. Wainwright 7th Annual Israel Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s Findings on Cannabis Compound’s Inhibition of Liver Cancer are Published in HEPATOLOGY and will be Presented at the AASLD’s The Liver Meeting® 2021 Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite’s NASH Patents Granted and Allowed in Japan, Hong Kong, and Mexico
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite CEO to Present Namodenoson’s Clinical Trial Data as Expert Speaker at 5th Annual Antifibrotic Drug Development Summit
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Positive Data from Phase IIa Can-Fite NASH Study Published in Leading Peer Reviewed Scientific Journal
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite CEO to Join Benzinga Medical Cannabis Panel and Deliver Company Presentation at Healthcare Small Cap Conference on September 29, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Participate in Three Upcoming Pharma Partnering Conferences
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Completes Patient Enrollment in Phase III Psoriasis Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Reports Second Quarter 2021 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Announces $10.0 Million Registered Direct Offering
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Yossi Borenstein, CEO and Founder of Shizim Group, has been Elected to the Can-Fite Board
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Gears Up to Initiate Pivotal Phase III Liver Cancer Study
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Enters Projected $3 Billion Veterinary Osteoarthritis Market: Signs Agreement with Vetbiolix for Development of Piclidenoson for Pets
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite Receives Notice of Patent Allowance in China for NASH Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite To Initiate Phase IIb NASH Study with its Drug Candidate Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
From Can-Fite BioPharma Ltd.
Via Business Wire
Tickers CANF
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.